First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligi…
この記事を読む
記事一覧 8ページ
この記事を読む
初回治療としてのセルぺルカチニブ
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. Zhou C et al.N Engl J Med. 2023…
この記事を読む
FLAURA2: 抗がん剤＋オシメルチニブまずPFS優越を証明
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. Planchard D et al.N Engl J Med. 2023 Nov 8.Epub…
この記事を読む
高齢者免疫療法の予後予測
Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD…
この記事を読む
ロルラチニブとALKバリアント3
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Typ…
この記事を読む
免疫療法後は何をしても変わらない？
Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens…
この記事を読む
オシメルチニブとアファチニブ交替療法、耐性機序が興味深い
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single…
この記事を読む
肺炎のような粘液性肺腺癌の元は孤発型なのか？
Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics. Goto E et…
この記事を読む
T細胞エンゲ―ジャーは小細胞肺癌治療の新たな選択肢となるか？
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label…
この記事を読む
腫瘍治療電場療法、新たな希望か眉唾か
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-sm…